A Chicago-based executive with more than 29 years of experience working with Fortune 100 leaders in the healthcare industry has been named to the Board of Directors of ProCure Treatment Centers, Inc. (ProCure). Ron K. Labrum, 55, will join a board comprising of medical professionals to advance ProCure’s mission to improve the lives of patients with cancer by providing access to proton therapy, an alternative to standard radiation for many tumors.

Labrum currently serves as president and chief executive officer of Fenwal, Inc., a global leader in products and technologies that support and improve blood collection, processing and transfusion medicine. Prior to working with Fenwal, Labrum served in leadership roles with Cardinal Health, Allegiance Corporation, Baxter International and American Hospital Supply Corporation.

“Ron has a very extensive track record in leadership roles and has been directing his company into a phase of rapid growth,” said Hadley Ford, chief executive officer of ProCure. “His skills will complement those of others on our board as we continue to grow our network of proton therapy centers, with our third Center opening in Somerset, New Jersey in early 2012. We welcome his expertise.”

“I am delighted to be involved with ProCure as we strive to make proton therapy more readily available to cancer patients here and around the world,” said Labrum. “We all feel the impact of cancer in some way and I look forward to working to ensure patients have access to this significant advance in treatment. I’ve worked in healthcare for all of my professional life and know what an important difference an improved technology can have.”

To continue reading, please visit:
http://procure.com/MasterMedia/ProCureNamesRonKLabrumToBoardOfDirectors.aspx